These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 8370605)

  • 21. Subcutaneous recombinant human erythropoietin in hemodialysis and continuous ambulatory peritoneal dialysis.
    Pais MJ; Gaspar A; Santana A; Bruges M; Simões J
    Perit Dial Int; 1993; 13 Suppl 2():S541-3. PubMed ID: 8399660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Recombinant human erythropoietin: 18 months of continuous use in substitution hemodialysis].
    Canaud B; Polito-Bouloux C; Rivory JP; Donnadieu P; Taib J; Florence P; Mion C
    Nephrologie; 1990; 11(1):5-10. PubMed ID: 2374643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intraperitoneal administration of recombinant human erythropoietin.
    Frenken LA; Struijk DG; Coppens PJ; Tiggeler RG; Krediet RT; Koene RA
    Perit Dial Int; 1992; 12(4):378-83. PubMed ID: 1420497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Once weekly subcutaneous erythropoietin is an effective maintenance therapy in the treatment of anemia of end stage renal disease in patients on CAPD.
    Saleh A; Krane NK; Caballero M; Starks E
    Adv Perit Dial; 1991; 7():288-91. PubMed ID: 1680448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
    Lui SF; Law CB; Ting SM; Li P; Lai KN
    Clin Nephrol; 1991 Nov; 36(5):246-51. PubMed ID: 1752075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
    Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Subcutaneous erythropoietin administration in predialysis patients: a single centre prospective study.
    Branger B; Vécina F; Zabadani B; Balducchi JP; Fourcade J
    Nephrol Dial Transplant; 1995; 10 Suppl 6():36-9. PubMed ID: 8524492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased response to subcutaneous erythropoietin on type I diabetic patients on CAPD: is there a synergistic effect with insulin?
    Fernandez-Reyes MJ; Selgas R; Bajo MA; Jimenez C; Del Peso G; Sanchez MC; Dapena F; De Alvaro F
    Perit Dial Int; 1995; 15(6):231-5. PubMed ID: 7578499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
    Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
    Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medium term response to H-R erythropoietin in CAPD patients: the influence of erythropoietin plasmatic levels and the effects on peritoneal transport capacity.
    Bajo MA; Selgas R; Miranda B; Fernandez-Zamorano A; Borrego F; Romero JR; Caparros G; Riñon C; Sanchez Sicilia L
    Adv Perit Dial; 1991; 7():296-300. PubMed ID: 1680450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effectiveness of and tolerance to human recombinant erythropoietin in the treatment of kidney failure anemia in children undergoing continuous peritoneal dialysis. Multicenter study].
    Parchoux B; Broyer M; Cochat P; Burguet A; Menget A; Benoît D; Nivet H; Fischbach M; Geisert J; Dabout D
    Pediatrie; 1993; 48(5):397-401. PubMed ID: 7777395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erythropoietin response and route of administration.
    Taylor JE; Belch JJ; Fleming LW; Mactier RA; Henderson IS; Stewart WK
    Clin Nephrol; 1994 May; 41(5):297-302. PubMed ID: 8050210
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multicenter study with once a week or once every two weeks high-dose subcutaneous administration of recombinant human erythropoietin in continuous ambulatory peritoneal dialysis.
    Nomoto Y; Kawaguchi Y; Kubota M; Tagawa H; Kubo K; Ogura Y; Shoji T; Kawada Y; Koshikawa S; Mimura N
    Perit Dial Int; 1994; 14(1):56-60. PubMed ID: 8312416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of subcutaneous erythropoietin in CAPD patients.
    Piraino B; Johnston JR
    Clin Nephrol; 1990 Apr; 33(4):200-2. PubMed ID: 2350907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Li H; Wang SX
    Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
    Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
    J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experience with subcutaneous erythropoietin in CAPD patients.
    Bailie GR; Plitnick R; Eisele G; Clement C; Rasmussen R
    Adv Perit Dial; 1991; 7():292-5. PubMed ID: 1680449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of erythropoietin treatment on nutritional status of continuous ambulatory peritoneal dialysis patients.
    Balaskas EV; Melamed IR; Gupta A; Bargman J; Oreopoulos DG
    Perit Dial Int; 1993; 13 Suppl 2():S544-9. PubMed ID: 8399661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inflammation, peritoneal transport, and response to erythropoietin in peritoneal dialysis patients.
    Pilkey RM; Morton AR; Iliescu EA
    Adv Perit Dial; 2001; 17():153-7. PubMed ID: 11510266
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Daily subcutaneous administration of recombinant human erythropoietin (rhEPO) in peritoneal dialysis patients: a European dose-response study.
    Faller B; Slingeneyer A; Waller M; Michel C; Grützmacher P; Müller HP; Barany P; Grabensee B; Issad B; Schmitt H
    Clin Nephrol; 1993 Sep; 40(3):168-75. PubMed ID: 8403573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.